InvestSMART

Nuix Limited (ASX:NXL)

ALERT: Price-sensitive ASX Announcement for NXL
Current share price for NXL : $1.835 0.475 (34.93%)+
Announcement
Release
23 Feb 2026 8:32AM
Price at Release
$1.360
Full Release
download
Summary
Nuix Limited announced its half-year results for the period ending December 31, 2025, highlighting an 8.4% growth in their Annualised Contract Value (ACV) to $234.4 million and a significant revenue increase of 15.2% to $121.2 million. The company reported a strong rise in Adjusted Management EBITDA by 42.6% and Statutory EBITDA by 72.7%, showcasing efficient operational leverage. The Nuix Neo platform was a key growth driver, with its ACV increasing by 148% to $46.8 million and expanding its customer base. Nuix also maintained its ACV guidance range for the full year at $240 million to $260 million. The company emphasized its strategic focus on sales transformation, product development, and operational efficiency, supported by its comprehensive Nuix Neo Migration Program and AI-enabled platform advantages. A notable development was the announced acquisition of Linkurious, which aims to enhance Nuix's graph visualization capabilities. The announcement also noted a robust financial position with a closing cash balance of $57.8 million and positive underlying and overall cash flow outcomes.
Key Points
  • Nuix's ACV increased by 8.4% to $234.4 million.
  • Revenue grew by 15.2% to $121.2 million.
  • Adjusted Management EBITDA rose by 42.6%.
  • Statutory EBITDA increased by 72.7%.
  • Nuix Neo platform's ACV rose by 148% to $46.8 million.
  • Full year ACV guidance maintained at $240 million to $260 million.
  • Nuix Neo Migration Program initiated.
  • AI integration strategy with 'Bring Your Own AI' framework.
  • Acquisition of Linkurious announced to enhance graph technology.
  • Positive cash flow with a $57.8 million closing cash balance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.